Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Orbimed Advisors Discloses 33.5% stake in Relypsa Inc (RLYP)

Sam Isaly’s Orbimed Advisors disclosed holding a 33.5% stake in Relypsa Inc (NASDAQ:RLYP), a company which recently conducted its Initial Public Offering. The fund reported, in a new filing, owning over 9.9 million shares of Relypsa, the stake being activist by nature. At the current value of Relypsa’s stock, the value of Orbimed’s holding amounts to $176.7 million. 


Relypsa Inc (NASDAQ:RLYP) went public in the middle of November, the company offered around 6.9 million shares, pricing them at $11 apiece. Underwriters also received an over-allotment option to acquire around 1.03 million shares. Net proceeds from the sale of shares amounted to nearly $78 million.

On November 20, Relypsa Inc (NASDAQ:RLYP) filed an 8-K report with the SEC. According to the filing, the company has restated several points regarding its incorporation, and the board, among other things authorized 300 million shares of common stock. Since the IPO, the stock of the company has gained over 55%.

According to the S-1 form of Relypsa Inc (NASDAQ:RLYP), Orbimed was the largest stockholder of the company prior to the IPO, and remained in its position after the company went public. The fund held around 7.5 million shares, plus warrants to purchase over 1.7 million shares, which in total deem the fund to ownership of 9.3 million shares, equal to 44% of the company. Following the IPO, Orbimed’s stake was reduced to 33.2%.

In the latest 13F, Orbimed Advisors reported its largest holding, which represents 4.8 million shares of Gilead Sciences, Inc. (NASDAQ:GILD), worth $300.4 million. The fund also disclosed holding 2.6 million shares of Amgen, Inc. (NASDAQ:AMGN), and 6.1 million shares of Merck & Co., Inc. (NYSE:MRK), among other holdings. The value of Amgen position amounts to $294.3 million, and Merck holding has a value of $289.3 million.

Disclosure: none

Recommended Reading:

Hedge Fund News: Barry Rosenstein, Steven Cohen & Carl Icahn

Jeffrey Gates, Gates Capital Add To Position in Darling International Inc. (DAR)

Mario Gabelli & GAMCO’s Latest Moves Involve Dover Motorsports, Inc. (DVD), and Mueller Industries, Inc. (MLI)